Who are Signifor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Somatuline Depot, Sandostatin, Octreotide LAR, Inj. Octreotide, Octreotide (drug), Sandostatin LAR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pasireotide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Signifor — Competitive Intelligence Brief

Signifor (PASIREOTIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin Analog [EPC]. Area: Oncology.

marketed Somatostatin Analog [EPC] Somatostatin receptor type 5 Oncology Recombinant protein Live · refreshed every 30 min

Target snapshot

Signifor (PASIREOTIDE) — Recordati. Signifor works by binding to somatostatin receptors on the surface of cells, mimicking the natural hormone somatostatin to reduce cortisol production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Signifor TARGET	PASIREOTIDE	Recordati	marketed	Somatostatin Analog [EPC]	Somatostatin receptor type 5	2012-01-01
Somatuline Depot	LANREOTIDE	Ipsen Pharma	marketed	Somatostatin Analog	Somatostatin receptor type 2	2007-01-01
Sandostatin	OCTREOTIDE	Novartis	marketed	Somatostatin Analog	Somatostatin receptor type 2	1988-01-01
Octreotide LAR	Octreotide LAR	Cedars-Sinai Medical Center	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
Inj. Octreotide	Inj. Octreotide	PVS Memorial Hospital	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
Octreotide (drug)	Octreotide (drug)	Lahore General Hospital	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
Sandostatin LAR	Sandostatin LAR	Pfizer	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Somatostatin Analog [EPC] class)

Recordati · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Signifor — Competitive Intelligence Brief. https://druglandscape.com/ci/pasireotide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab